Records of hypertensive patients who received standard treatment for ovarian cancer at Mass General show that those taking losartan* at the time of diagnosis lived an average of 30 months longer than those taking other hypertension drugs.
Losartan, which targets the angiotensin-signaling pathway, might improve the effectiveness of chemotherapy agents used to treat ovarian cancer.
Animal studies show reduced extracellular matrix collagen content in ovarian tumours, increasing blood supply, oxygen levels and drug delivery.
It is predicted that adding losartan as an adjunct to cancer therapy, could improve outcomes, improving survival for cancer patients.
No comments:
Post a Comment